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It is evident that the morning symptoms of rheumatoid
arthritis (RA) are linked to the circadian abnormal
increase in night inflammation, favoured by inadequate
cortisol secretion under conditions of active disease.
Therefore, exogenous glucocorticoid treatment is
recommended in RA at low doses since it may partially
act like a ‘replacement therapy’. The prevention/
treatment of the night upregulation of the immune/
inflammatory reaction (and related flare of cytokine
synthesis) has been shown to be more effective when
exogenous glucocorticoid administration is obtained
with a night-time-release formulation. Large-scale trials
documented that modified-release prednisone has
greater efficacy then morning prednisone for long-term
low-dose glucocorticoid treatment in patients with RA,
showing at least a more significant reduction in
morning joint stiffness. Interestingly, despite a
considerably higher cost than conventional prednisone,
chronotherapy with night-time-release prednisone was
recognised as a cost-effective option for patients with
RA not on glucocorticoids who are eligible for therapy
with biological disease-modifying antirheumatic drugs
(DMARDs). Moreover, since different cell populations
involved in the inflammatory process are particularly
activated during the night, other therapeutical
approaches used in RA, for example, conventional
DMARDs and non-steroidal anti-inflammatory drugs
(NSAIDs), should follow the same concepts of
glucocorticoid chronotherapy. Indeed, bedtime
methotrexate chronotherapy was found to improve RA
symptoms compared to the current standard dosing
methods, and several available NSAIDs (ie,
indomethacin, aceclofenac, ketoprofen, flurbiporfen,
lornoxicam) have been very recently modified in their
formulation, in order to obtain chronotherapeutical
effects in RA.
INTRODUCTION
It is well assessed that crucial clinical signs
and symptoms of rheumatoid arthritis (RA)
vary within a day and between days, and the
morning joint stiffness observed in almost all
patients with active RA is also considered one
of the most peculiar diagnostic criteria of the
disease.1
Similarly, other RA symptoms, such as joint
pain and functional disability, are commonly
most severe in the early morning by follow-
ing 24 h cycles, and are a consequence of
altered neuroendocrine and immune/
inflammatory activities.2
Therefore, it is not surprising that also in
other chronic inflammatory rheumatic dis-
eases, including polymyalgia rheumatica
(PMR) and ankylosing spondylitis, symptoms
of pain and stiffness typically are most prom-
inent during the early morning, similar to
RA.3
It is now evident that the morning symp-
toms, at least in RA, are linked to the circadian
increase in proinflammatory cytokines, as a
result of an increased night inflammation.
Indeed, cytokines, such as tumour necrosis
factor (TNF) α and interleukin (IL) 6, are
highly increased in patients with active RA in
the very late night hours, whereas they are
present at very low levels after noon.4
Following several signallings, it is now
evident that neuroendocrine circadian
rhythms play an important role in RA clinical
symptomatology.5 6
Key messages
What is already known about this subject?
▸ Morning clinical symptoms of rheumatoid arth-
ritis are linked to circadian abnormal increase of
night inflammation, favoured by inadequate cor-
tisol secretion.
What does this study add?
▸ Several evidences now seem to confirm that the
treatment of the night up-regulation of the
immune/inflammatory reaction at lest in rheuma-
toid arthritis, is more effective when exogenous
glucocorticoid administration is obtained with
nighttime-release chronotherapy.
How might this impact on clinical practice?
▸ Treatment of rheumatoid arthritis is starting to
include the concept of chronotherapy also for
the use of conventional DMARDs and NSAIDs.
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Proinflammatory night hormones, such as melatonin
(and prolactin), which follow a 24 h daily cycle, as well
as the full availability of bioenergies during the night,
are recognised among the triggers/enhancers for
increased release and serum concentrations of cyto-
kines7 8 (figure 1).
Interestingly, the nocturnal ability of the neuroendo-
crine system to mount an efficient inflammatory
response with related clinical effects also seems to be
involved in acute arthritis events such as gout attacks.
The circadian clock and RA
In all individuals, a circadian clock drives daily rhythms
in physiology necessary to synchronise the human func-
tions with the 24 h environment.9
Therefore, physiological functions under circadian
control include the sleep-wake cycle, heart rate, blood
pressure, body temperature, as well as endocrine gland
regulation (ie, gonadal and adrenal steroidogenesis)
and immune response. These daily rhythms are con-
trolled by a central pacemaker, which is found in a hypo-
thalamic region located above the optic chiasm called
the suprachiasmatic nucleus (SCN)10 (figure 2).
The SCN collects from the eyes the light inputs via the
retinohypothalamic tract. The central pacemaker syn-
chronises additional peripheral oscillators found locally
within organs, tissues and cells.10 These peripheral
clocks are synchronised by the central clock, but are self-
sustaining and can be entrained by external cues such as
temperature.
A bidirectional interaction between inflammation and
the circadian clock has been shown recently, and disrup-
tion of the clock has a significant effect on the perform-
ance of the immune system, with a possible impact on
the pathogenesis of RA. Conversely, inflammation can
directly alter cellular expression of core clock genes.11
Figure 1 Circadian sequence of
nocturnal hormone secretion that
induces activation (melatonin,
prolactin) and/or dowregulation
(cortisol) of the immune
inflammatory response during the
night. Clinical consequences of
altered hormonal balance in
rheumatoid arthritis (RA) include
morning symptoms such as joint
stiffness and pain.
Figure 2 The daily
neuroimmunoendocrine rhythms
(gonadal, adrenal, pituitary
hormones) are controlled by a
central pacemaker, which is
found in a hypothalamic region
called the suprachiasmatic
nucleus (SCN) of the central
nervous system (CNS). APC,
antigen presenting cell; DHEA,
dehydroepiandrosterone; Th,
T helper cell; Treg, regulatory
T cell.
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Possible causes of disruption of the clock should
include jet lag, causing a desynchrony between the
internal clock and the environment, and the condition
of night shift-workers. Generally, constant shifts in the
daily schedule are detrimental to health and have been
linked with an increased incidence of a number of
chronic diseases such as cardiovascular disease, meta-
bolic syndromes, diabetes, irritable bowel syndrome and
even cancer.12
Interestingly, a study in 2010 provided a significant
link also between shift work and an increased risk of RA
(in women).13
Once again, the endocrine system mediates the dis-
semination of timing signals from the SCN throughout
the body and to the immune system, and two night hor-
mones act as circadian agents—glucocorticoids and
melatonin (prolactin). Both are important in regulation
of the immune/inflammatory response, and contribute
to the pathogenesis of RA14 15 (figure 2).
Insufficient endogenous glucocorticoid secretion in RA
Acute proinflammatory events, such as bacterial infec-
tions, activate the hypothalamus-pituitary-adrenal (HPA)
axis response, leading to high levels of circulating ACTH
and cortisol. In particular, daily production of cortisol
can increase by a factor of 18 in extreme situations (ie,
first days of sepsis).16
Importantly, this strong stimulation only lasts for a
short period of time (a few days). Conversely,
inflammation-associated downregulation of the HPA axis
activity in chronic inflammation, such as in RA, is
related both to circulating cytokines that can harm the
HPA axis on all levels (hypothalamus, pituitary gland
and adrenal gland) and to a consequential partial
adrenal insufficiency17 (figure 3).
The proinflammatory cytokines IL-1β and TNF are the
main factors which interfere with several steps of
steroidogenesis.
Inadequate secretion of endogenous glucocorticoids is
also evident by studying circadian rhythms of serum
levels of cytokines and steroids. The circadian rhythm of
serum cortisol with respect to amplitude and period is
similar in healthy controls and in patients with RA with
mild to moderate disease. In contrast, serum levels of
IL-6 are almost 10 times higher and the circadian
rhythm is quite different in controls and in patients with
RA. Therefore, despite raised serum concentrations of
IL-6, the amplitude of the circadian rhythm of cortisol is
not increased as expected, which is indicative of inad-
equate cortisol secretion under adrenal stress related to
persistent active disease18 (figure 3).
Furthermore, it has been demonstrated that the deg-
radation of the bioactive cortisol to the biologically
inactive cortisone is increased when studying mixed syn-
ovial cells of inflamed tissue. This phenomenon is due to
the increased numbers of cells positive for the degrading
enzyme 11β-hydroxysteroid dehydrogenase type 2 and to
a decreased reactivation of cortisone to cortisol.19
The clinical and biochemical improvement observed
after glucocorticoid therapy in patients with RA
appeared in a previous study to be attributed to a direct
dampening of proinflammatory factors, as well as to the
restoration of the steroid milieu.20
In conclusion, since cortisol is the strongest endogen-
ous anti-inflammatory substance, its abnormal downre-
gulation and hyposecretion during the night in chronic
diseases may justify the presence of the early morning
clinical symptoms in patients with RA, while in contrast
the synthesis of melatonin is still high and enhancing
the night inflammatory reaction.20
Figure 3 Basically, melatonin
increases and cortisol reduces
the immune/inflammatory reaction
following a circadian rhythm.
Reduced efficiency of the HPA
axis activity related to chronic
stimulation, such as in
rheumatoid arthritis (RA), can
induce a partial adrenal
insufficiency. The consequence is
reduced cortisol availability and
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The role of melatonin in RA
The pineal hormone melatonin exerts a variety of
effects on the immune system. Generally, melatonin acti-
vates immune cells and enhances inflammatory cytokine
and nitric oxide production following a circadian
rhythm.5 14
Previous investigation showed that in patients with RA
and in healthy participants, melatonin levels increase
progressively from 20:00 to the early morning hours and
they reach peak levels at midnight in patients with RA,
which was at least 2 h earlier than in healthy controls.14
Subsequently, melatonin concentrations in patients
with RA reach a plateau that lasts for 2–3 h; this was not
observed in controls. After 2:00, melatonin levels
decrease similarly in patients with RA and in healthy
participants. The studies confirmed that the nocturnal
rhythm of melatonin occurs also in patients with RA, but
with an earlier peak and a longer duration in the early
morning.5 14
As a matter of fact, production of several cytokines
such as IFNγ, IL-1, IL-6, TNF-α, IL-2 and IL-12 (Th1
cytokines) reach the peak during the night, at the same
time that melatonin serum levels are highest and plasma
cortisol is lowest.
Interestingly, melatonin was found detectable in high
concentration in synovial fluids from patients with RA,
and binding sites for melatonin were present in synovial
macrophages.21 In addition, cultured RA synovial macro-
phages respond to melatonin stimulation with an
increased proinflammatory cytokine production.22
Therefore, it is not surprising that melatonin treatment
does not improve RA clinical status, but, to the contrary,
may further enhance the inflammatory reaction as previ-
ously shown.23
Chronotherapy with low-dose glucocorticoids in RA
Exogenous glucocorticoid treatment is today recom-
mended at low doses in RA since it may act as a ‘replace-
ment therapy’ in the presence of decreased endogenous
cortisol availability.24 25 However, different mineralocor-
ticoid and glucocorticoid activities are still important
aspects that differentiate between exogenous (ie, thera-
peutic) and endogenous (ie, physiological) glucocorti-
coids.24 Therefore, exogenous synthetic glucocorticoids
exhibit a more selective glucocorticoid/anti-
inflammatory action (less mineralocorticoid effects), as
well as have a different biological half-life, plasma
kinetics, metabolism and non-genomic high-dose effects
compared to cortisol (hydrocortisone).
In any case, long-term exogenous glucocorticoid
administration may interfere with the HPA axis function
and with the circadian cortisol production.
Interestingly, a reduction of mean initial low-dose
from 10.3 to 3.6 mg/day (prednisone) on long-term
glucocorticoid therapy in RA has been observed in one
recent analysis during the period 1980–2004.26
The more specific items of the EULAR recommenda-
tions for the management of RA relate to starting
disease-modifying antirheumatic drug (DMARD)
therapy in early disease using a conventional DMARD
strategy in combination with low-dose glucocorticoids.27
In addition, there is evidence that glucocorticoid
therapy, especially long-term low-dose treatment, may
slow radiographic progression by at least 50% when
given to patients with early RA, in agreement with the
conventional definition of DMARD.28
Glucocorticoids exert important genomic effects on
cellular immunity and, given the existence of cellular cir-
cadian rhythms, therefore the prevention of the night
upregulation of immune cell activity (and related flare
of cytokine synthesis) with their exogenous administra-
tion between 6:00 and 8:00 may not be optimal since it
is too late to interfere with the activation of the noctur-
nal inflammatory process.29
Since it has been established that pain, stiffness and
functional disability show maximum levels in the early
morning hours, it is now clear that preventing the noc-
turnal rise of proinflammatory cytokines by glucocorti-
coids is more effective than treating established
symptoms in the morning30 (figure 4).
In addition, several inflammatory pathways also involv-
ing the central nervous system involvement in RA (ie,
pain perception) might be better controlled by chrono-
therapy, resulting in increased sleep quality and reduc-
tion of related depressive symptoms.6
The first reliable clinical study showing the superiority
of night versus morning administration of glucocorti-
coids in RA was published in 1964.31
Fifty-six patients with RA were included in a double-
blind trial. None of the patients had at any time taken a
dose of glucocorticoids larger than 5 mg prednisolone.
In this trial, patients took one tablet at 22:00 and a
second, identical in appearance, in the morning; one
tablet contained 5 mg prednisolone and the other was a
placebo. For each patient, the 4-week trial was divided
into 2-week periods. As result, the 5 mg prednisolone
given at night was found to reduce or eliminate
morning stiffness in the majority of patients with RA.
The effect was quickly apparent and was confirmed by
altering the time of administration from night to
morning and vice versa in random fashion and under
double-blind conditions.31
Twenty years later, in 1984, 41 patients with RA main-
tained on low-dose prednisolone (mean 5.8 mg) partici-
pated in a double-blind crossover study to again
determine the effect of timing (morning or night) of
prednisolone dosage on morning stiffness.32
The patients were asked to take their study tablets
(70%= or <5 mg/day) on retiring (22:00–23:00) and on
rising (6:00—7:00) with milk but not a major meal.
Prednisolone given at night resulted in a significantly
shorter duration of morning stiffness (p=0.0001) than
did an equivalent dose given in the morning. In add-
ition, non-parametric statistical analysis (sign test)
showed a significant preference (p<0.05) for the night
therapy.
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Finally, in 1997, 26 glucocorticoid-untreated patients
with RA were randomly divided into two equal groups
and allocated to low doses of prednisolone at either 2.00
or 7.30.33
Administration of low doses of prednisolone (5 or
7.5 mg daily) at 2:00 after only 5 days showed favourable
effects on the duration of morning stiffness (p<0.001),
joint pain (p<0.001), Lansbury index (p<0.001), Ritchie
index (p<0.001) and morning serum concentrations of
IL-6 (p<0.01). The other study group showed minor but
significant effects on morning stiffness (p<0.05) and cir-
culating concentrations of IL-6 (p<0.05). The study con-
firmed that administration of low doses of
glucocorticoids with a rather short biological half-life
seems to improve acute RA symptoms if it precedes the
period of circadian flare in inflammatory activity, as
defined by enhanced IL-6 synthesis.
More recently, the most advanced approach for the
low-dose prednisone chronotherapy in RA included the
modified-release prednisone, a timing drug release with
administration at 22:00, and releasing prednisone around
2:00–3:0034(figure4).Themeanrelativechangeinduration
ofmorning joint stiffness from baseline to end of this study
was significantly higher with modified-release prednisone
thanwithimmediate-releaseprednisone(−22.7%vs−0.4%;
difference=22.4% (95% CI 0.49 to 44.30); p=0.045). The
absolute difference between the treatment groups
was 29.2 min (95% CI −2.59 to 61.9) in favour of modified-
release prednisone (p=0.072). Finally, in the prednisone
modified-release group, a mean reduction of 44.0 (SD
136.6) minutes was achieved compared with baseline.
However, in this study (Circadian Administration of
Prednisone in Rheumatoid Arthritis; CAPRA-1), patients
with RA treated in the ‘control’ arm were given their
daily dose of prednisone early in the morning, and not
at bedtime, whereas it should have been administered
similarly in the late evening in order to demonstrate the
superiority of modified-release prednisone over regular
prednisone to reduce morning stiffness.
In addition, no studies compared modified-release
prednisone with the standard prednisone but at dosage
devided between morning and bedtime.
Treatment with evening modified-release prednisone
for up to 12 months was shown to be generally well toler-
ated, with an overall similar safety profile compared with
evening placebo or morning regular prednisone.34 As
expected, the incidence of adverse events was higher
over the 12-month period than over the 3-month period,
even if the increase was not proportional to the duration
of treatment.
As a matter of fact, the incidence of severe adverse
events during the first 3 months of treatment was 2.4%
compared with only 3.3% in patients receiving 12 months
of modified-release prednisone administration.34
Large-scale trials documented that modified-release
prednisone has greater efficacy for long-term low-dose
glucocorticoid treatment in patients with RA, showing a
significant reduction in morning joint stiffness/fatigue
in addition to all known therapeutic effects with conven-
tional prednisone and a similar safety profile but
without additional suppression of the HPA axis.35 36
The reported studies confirmed that the specific
timing of exogenous prednisone availability, linked to
the interaction between IL-6 and the HPA axis, may
correct a postulated deficiency in HPA control in RA.37
Effects of the glucocorticoid chronotherapy in RA
Single-centre crossover studies were conducted recently
in patients with RA in order to compare the pharmaco-
kinetics of a single 5 mg oral dose of modified-release
Figure 4 Low-dose
glucocorticoid chronotherapy in
rheumatoid arthritis (RA) include
the night-time-release
prednisone, a timing drug release
formulation with administration
around 22–23 (22:00–23:00) and
releasing prednisone around
2:00–3:00. Other therapeutical





drugs (NSAIDs), should follow the
same concept of glucocorticoid
chronotherapy.
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prednisone and conventional prednisone, as well as the
effect of food, on bioavailability.38
No substantial difference in pharmacokinetic para-
meters of the formulations, apart from the programmed
delay in release of prednisone from the
night-time-release formulation, was observed. In add-
ition, administration after a full or light meal did not
affect pharmacokinetic characteristics; in contrast, the
bioavailability was reduced under fasted conditions.
Pharmacokinetic evaluation in patients with RA con-
firmed that modified-release prednisone tablets taken at
bedtime with or after an evening meal result in pro-
grammed release from 4 to 6 h after intake.38
The effects of long-term low-dose chronotherapy with
modified-release prednisone on the HPA axis have been
carefully investigated in patients with RA.39 The increase
of cortisol plasma concentrations after injection of
corticotropin-releasing hormone (CRH) was 5.5 (SD
4.37) μg/dL on regular-morning prednisone at baseline
and 5.3 (4.07) μg/dL on modified-release prednisone at
12 months.
Switching from morning to night-time-release prednis-
one did not influence adrenocortical function, and nor
did long-term treatment of up to 12 months with
modified-release prednisone. Finally, no worsening of
adrenal impairment was observed on treatment with
night-time-release prednisone in patients with low
responsiveness to CRH testing before treatment with
such an approach.
A further observational study assessed functional
ability in patients with RA treated with modified-release
prednisone under conditions of normal clinical prac-
tice.40 Interestingly, the dose of prednisone was signifi-
cantly reduced after 9 months of treatment (from 5.0 to
4.4 mg/day, p<0.001) with modified-release prednisone
and fewer patients with RA required biological DMARD
treatments. The advantages related to lowering the
mean dose of modified-release prednisone during long-
term treatment could include a better safety profile by
reducing the risk of adverse effects.
To assess if modified-release prednisone taken at
bedtime is confirmed to be more effective than prednisone
taken in the morning, a total number of 950 outpatients
with RA treated with different morning glucocorticoids
and DMARDs (15.8% biologics, 83.7% methotrexate,
10.5% leflunomide) were switched from immediate-release
prednisone or 6-methyl (6M)-prednisolone to low-dose
modified-release prednisone and followed for 4 months.41
In detail, 513 patients with RA were switched to
modified-release prednisone from immediate-release
prednisone (9.4±5.4 mg) and 437 from 6M-prednisolone
(6.7±3.7 mg). At the time patients with RA completed
4 months (904, 96.8%) of modified-release prednisone
treatment after switch from immediate-release prednis-
one or 6M-prednisolone, morning stiffness duration,
pain intensity, patient and physician global assessment
improved significantly (p<0.001) when compared to
basal time. Moreover, mean daily modified-release
prednisone dosage also decreased from 8.2 to 6.7 mg
between baseline and end point (16 weeks).
Generally, glucocorticoid-naive patients with RA seem
to be the best responders to the night-time-release pred-
nisone. In addition, switching from other glucocorti-
coids to low-dose modified-release prednisone improved
significantly the disease outcomes over 4 months, as
shown in the open, unblinded study. 41
Interestingly, in a very recent study assessing the effi-
cacy and safety of night-time-release prednisone versus
morning-release prednisone in newly diagnosed patients
with PMR, there was a clear consistent trend for a signifi-
cantly stronger effect of modified-release prednisone
across most secondary efficacy end points at week 4, with
a discernible treatment difference observed as early as
week 1.42
In addition, night-time-release prednisone reduced
IL-6 levels in a more significant manner versus
morning-release prednisone (p<0.01).
After safety and effectiveness of chronotherapy was
assessed, it was evaluated in patients with RA the cost-
effectiveness of modified-release formulations compared
with immediate-release prednisone and based on dur-
ation of morning stiffness.43
Health benefits were evaluated as quality-adjusted life
years and the final output was the incremental cost-
effectiveness ratio. Efficacy data were derived from the
original study on a modified-release prednisone study,
drug costs from the British National Formulary.
As expected, the mean treatment costs per patient
were found to be higher for night-time-release prednis-
one than for immediate-release prednisone. The analysis
pointed out that the mean treatment costs per patient
per year were higher for modified-release prednisone
(£649.70) than for regular prednisone (£46.54).
However, the model generated an incremental QALY
of 0.044 in favour of modified-release prednisone, which
resulted in an ICER of £13 577.
Probabilistic sensitivity analysis reported that
modified-release prednisone had an 84% probability of
being cost-effective at a willingness-to-pay threshold of
£30 000 per QALY.
In synthesis, this analysis demonstrates that, on the
basis of the CAPRA-1 trial, modified-release prednisone
is a cost-effective treatment option when compared with
immediate-release prednisone for patients with RA with
morning stiffness over 1 year.
A further study on cost-effectiveness analysed the
effects of a 12-week treatment with modified-release
prednisone versus placebo on the costs of drug treat-
ment of RA.44
The results showed 11–13% more patients on
modified-release prednisone than on placebo treatment
reached significant improvement and dropped below
reimbursement thresholds of disease activity (DAS28)
in the countries of the Netherlands, Belgium and the
UK. Interestingly, assuming 1 year of biologics cost
€15 000 and MR-pred costs €1/day, €396 are saved in
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each patient with RA by delaying biological treatment by
12 weeks.
The study again concluded that despite a considerably
higher cost than conventional prednisone, chronother-
apy with night-time-release prednisone is a cost-effective
option for patients with RA not on glucocorticoids who
are eligible for therapy with biological DMARDs.44
Other approaches to chronotherapy in RA
A recent study showed that in RA some immune cell
populations (ie, monocytes) lose their normal circadian
rhythms, and others establish new ‘inflammatory’ circa-
dian rhythms.45
Therefore, since different cells involved in the inflam-
matory process are particularly activated during the
night, other therapeutical approaches used in RA, for
example, with DMARDs and non-steroidal anti-
inflammatory drugs (NSAIDs), should follow the same
concepts of glucocorticoid chronotherapy.
As a matter of fact, the circadian activation of the cells
involved in the RA immune/inflammatory response
represents the preferential target for conventional and
biologic DMARDs, therefore, also the administration of
antiproliferative drugs (ie, methotrexate, leflunomide,
cyclophosphamide, etc.) should consider those rhythms.
This hypothesis was tested in an in vivo investigation
using an animal model of arthritis, and showed that the
optimal dosing time, associated with the 24 h cycling of
TNF-α, could result in the most efficient methotrexate
antiinflammatory activity and the most effective decrease
of TNF-α.46
A successive clinical study has confirmed that bedtime
methotrexate chronotherapy (3 times a week once a day
in the evening) can improve RA symptoms compared to
the current standard dosing methods47 (figure 4).
On the other hand, the migration/activation of neu-
trophilic polymorphonuclear cells in the inflammatory
site follows night rhythms, and starting early in the
1980s, various controlled-release NSAIDs have been
explored for administration-time differences in their
symptomatic effects48 (figure 4).
An early double-blind crossover study design that
included multiple (4 to 6 times per day) pain, stiffness
and hand strength self-assessments in patients with RA
reported that a twice-daily flurbiprofen schedule that
lacked an evening dosing time (ie, 200 mg in the
morning and 200 mg at midday) was less effective in
modulating morning RA signs and symptoms than ones
that did (200 mg in the morning and 200 mg at bedtime
or 200 mg at midday and 200 mg at bedtime).49
A similar study design found that an evening once-
daily scheduling of 75 mg (indomethacin formulation
25 mg immediate-release combined with 50 mg
controlled-release) resulted in much greater control of
morning OA symptoms compared to once-daily morning
(breakfast time) or once-daily midday (lunchtime)
schedules.50
Recently, a pH-responsive dual pulse multiparticulate
dosage form containing ketoprofen was tested in RA
and was found to be able to relieve circadian symptoms
during midnight and early morning.51
More recently, with the main intent of delivering
maximum concentration of indomethacin available from
the dosage form, an oral compression-coated tablet was
developed with a predetermined lag time of 6 h before
immediate release and which is suitable for treating
night RA circadian inflammation.52
Similar results should be obtainable in chronopharmaco-
logical treatment of morning RA symptoms with recently
synthesised eudragit-coated aceclofenac-loaded pectin
microspheres or lastly with a pH-triggered delayed-release
colon-specific aceclofenac microspheres.53 54
Very recently, a formulation of mini-tablets-filled-
pulsincap delivering lornoxicam for chronotherapy of
RA was synthesised for night administration.55 The opti-
mised pulsincap formulation releases lornoxicam after a
lag time of 5 h and a maximum portion of the drug will
be released in the early morning hours.
In conclusion, the ongoing research on biological
rhythms in inflammation and the synthesis of circadian
agents is leading to a better understanding of the
mechanisms of inflammation and to a more rational use
of the drugs in patients with RA.
CONCLUSIONS
In patients with RA, the stiffness and functional joint dis-
ability characterising the early morning hours are
related to the night activation of the immune/inflamma-
tory response.
The prevention/treatment of the upregulation of
immune cell activity (and related flare of cytokine syn-
thesis) has been shown to be more effective when
exogenous glucocorticoid availability is obtained at
night-time. The positive results obtained in RA with
modified-release prednisone low-dose chronotherapy,
following the chronobiology of the disease, seem applic-
able in RA even for other agents such as conventional
DMARDs and NSAIDs.
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